���重受体激动剂的分子设计 — Deep Dive

By Editorial Desk · published 2025-09-15 · last reviewed 2025-10-30 · Faq

A practical reference on body composition: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2025-10-30 and is reviewed periodically as new material appears.

三重受体激动剂的分子设计

该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。

retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。

三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。

Retatrutide Background and Receptor Activity

The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.

Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.

Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.

Retatrutide at a glance

Trial Endpoints and Interpretation

Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.

Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.

Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.

Related pages on this site

• Quality briefing
• Balanced dataset
• Seasonal toolkit
• Measured update
• Regional update
• Seasonal comparison
• Lightweight collection
• Sustainable primer

瑞他鲁肽开发背景

开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。

与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。

瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。

Background from the literature

== Provitamin A activity == Plant carotenoids are the primary dietary source of provitamin A worldwide, with β-carotene as the best-known provitamin A carotenoid. Others include α-carotene and β-cryptoxanthin. Carotenoid absorption is restricted to the duodenum of the small intestine. One molecule of β-carotene can be cleaved by the intestinal enzyme β,β-carotene 15,15'-monooxygenase into two molecules of vitamin A.

Embalming is the practice of preserving a body against decay and is used in many cultures. Mummification is a more extensive method of embalming, further delaying the decay process. Bodies are often buried wrapped in a shroud or placed in a coffin (or in some cases, a casket). A larger container may be used, such as a ship. In the U.S., coffins are usually covered by a grave liner or a burial vault, which prevents the coffin from collapsing under the weight of the earth or floating away during a flood. These containers slow the decomposition process by (partially) physically blocking decomposing bacteria and other organisms from accessing the corpse. An additional benefit of using containers to hold the body is that if the soil covering the corpse is washed away by a flood or some other natural process then the corpse will still not be exposed to open air.

For people of Black African, African-Caribbean, South Asian and Chinese descent the recommendation to start prevention starts at the BMI of 27.5. A study based on a large sample of people in England suggest even lower BMIs for certain ethnic groups for the start of prevention, for example 24 in South Asian and 21 in Bangladeshi populations.

== G == GAG – gamma globulin – gamma interferon – ganglion – GART – gastrointestinal (GI) – gene – gene therapy – genetic engineering – genital ulcer disease – genital warts – genitourinary tract – genome – genotypic assay – germinal centers – giardiasis – globulins – glycoprotein – gonorrhea – gp120 (gp120) – gp160 (gp160) – gp41 (gp41) – granulocyte – granulocyte macrophage-colony stimulating factor (GM-CSF) – granulocyte-colony stimulating factor (G-CSF) – granulocytopenia

Sources: en.wikipedia.org

Further detail

=== Pseudomonas syringae pv. tomato strain DC3000 and Arabidopsis thaliana === As mentioned above, the genome of P. syringae pv. tomato DC3000 has been sequenced, and approximately 40 Hop (Hrp Outer Protein) effectors - pathogenic proteins that attenuate the host cell - have been identified. These 40 effectors are not recognized by A. thaliana thus making P. syringae pv. tomato DC3000 virulent against it - that is, P. syringae pv. tomato DC3000 is able to infect A. thaliana - thus A. thaliana is susceptible to this pathogen. Many gene-for-gene relationships have been identified using the two model organisms, P. syringae pv. tomato strain DC3000 and Arabidopsis. The gene-for-gene relationship describes the recognition of pathogenic avirulence (avr) genes by host resistance genes (R-genes). P. syringae pv. tomato DC3000 is a useful tool for studying avr: R-gene interactions in A. thaliana because it can be transformed with avr genes from other bacterial pathogens, and furthermore, because none of the endogenous hops genes is recognized by A. thaliana, any observed avr recognition identified using this model can be attributed to recognition of the introduced avr by A. thaliana. The transformation of P. syringae pv. tomato DC3000 with effectors from other pathogens have led to the identification of many R-genes in Arabidopsis to further advance knowledge of plant pathogen interactions.

The same month, she partnered with Models of Diversity to appear in a billboard campaign alongside a group of other women, raising awareness about the lack of diversity within fashion weeks. Collins said of the campaign that she was "Getting a bit sick of the fashion industry still not letting plus-size women walk the runways" adding that she felt "plus-size fashion was at an all time low" and that she was "shocked by how bad the regular sites had become". In November 2024, Collins attended the Swansea Christmas Parade as part of a collaboration with McDonald's for their "Gift Drop" campaign. For the event, she dressed in a red ball gown and offered the public the chance to try items from the companies' Festive Menu ahead of its launch, serving from a food van. In December 2024, after collaborating with Baileys Irish Cream and appearing at one of their events earlier in the year, she hosted The Baileys Christmas Sip and Sing event where she performed alongside The Gold Collective choir. Of the event, Collins said: "Tis the season to Baileys, honey! Christmas is all about bringing people together for a bit of festive joy, a Christmas singalong, and of course, some Baileys". In June 2025, Collins collaborated with the motorised kitchen appliances company Ninja to promote their slushy machine Ninja SLUSHi. In a social media video promoting the product, Collins was appointed the "GCEO" and expresses her distaste in the employees slushy ideas at a board meeting, before introducing her own that are based on her, named the "Gemma Tom Collins" and "Brentwood Bellini" respectively.

=== Rare === Suicide through disinhibition Psychosis Incontinence Paradoxical behavioural disinhibition (most frequently in children, the elderly, and in persons with developmental disabilities) Rage Excitement Impulsivity The long-term effects of clonazepam can include depression, disinhibition, and sexual dysfunction.

Sources: en.wikipedia.org

Frequently asked questions